Subcategory Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Medical/Pharmacologic$10,960,296.00
Fiscal Year: 2010
  

Download 2010 Medical/Pharmacologic projects (EXCEL)
This subcategory includes research on drugs (e.g., antidepressants, anticonvulsants, antipsychotics, anxiolytics, melatonin, and stimulants) to treat autism and its co-occurring conditions, as well as medical therapies such as transcranial magnetic stimulation (TMS).
Graph: The subcategories for Question 4 illustrate the many approaches to treatments and interventions supported by autism research funders. The largest amount of funding supported projects to develop Model systems and therapeutic targets (35%), followed by research on Behavioral interventions (29%). Medical/Pharmacologic interventions received 16% of funding, classroom-based interventions (Educational) received 10% of funding, and Technology-based interventions and supports received 7% of funding. The subcategories with the smallest amounts of funding included Occupational, physical, and sensory-based (2%) and Complementary, dietary, and alternative (1%).
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Strategic Plan Objective Institution
Treatment of sleep problems in children with autism spectrum disorder with melatonin: A double-blind, placebo-controlled study Hopkins, Bobbi Q4.S.A Baylor College of Medicine
Treatment of sleep problems in children with autism spectrum disorder with melatonin: A double-blind, placebo-controlled study Hopkins, Bobbi Q4.S.A Baylor College of Medicine
Autism Intervention Research Network on Physical Health (AIR-P network) Perrin, James Q4.S.A Massachusetts General Hospital
Intranasal oxytocin for the treatment of children and adolescents with autism spectrum disorders (ASD) Anagnostou, Evdokia Q4.S.C Holland Bloorview Kids Rehabilitation Hospital
ACE Network: Early pharmacotherapy guided by biomarkers in autism Chugani, Diane Q4.S.F Wayne State University
Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART) Devane, C. Lindsay Q4.S.F Medical University of South Carolina
1/3-Atomoxetine placebo and parent training in autism Handen, Benjamin Q4.S.F University of Pittsburgh
Predictors of effects of propranolol on language & connectivity in autism Beversdorf, David Q4.S.F University of Missouri
3/3-Atomoxetine placebo and parent training in autism Smith, Tristram Q4.S.F University of Rochester
2/3-Atomoxetine placebo and parent training in autism Aman, Michael Q4.S.F Ohio State University
Clinical Trials Network Staff Member Q4.L.A Autism Speaks (AS)
Association of cholinergic system dysfunction with autistic behavior in fragile X syndrome: Pharmacologic and imaging probes Reiss, Allan Q4.L.A Stanford University
ACE Center: The pharmacogenetics of treatment for insistence sameness in autism Owley, Thomas Q4.L.A University of Illinois at Chicago
ACE Center: Understanding repetitive behavior in autism McCracken, James Q4.L.A University of California, Los Angeles
Trial of a glutamate antagonist in the treatment of OCD and autistic disorders Swedo, Susan Q4.L.A National Institutes of Health
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial Johnson, William Q4.L.A University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial Stein, Peter Q4.L.A University of Medicine & Dentistry of New Jersey
Neuronal nicotinic receptor modulation in the treatment of autism: A pilot trial of mecamylamine Arnold, L. Eugene Q4.L.A The Ohio State University
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial Novotny, Sherie Q4.L.A University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School
The effects of oxytocin on complex social cognition in autism spectrum disorders Bartz, Jennifer Q4.L.A Mount Sinai School of Medicine
Randomized phase 2 trial of RAD001 (an MTOR inhibitor) in patients with tuberous sclerosis complex Sahin, Mustafa Q4.L.A Childrens Hospital Boston
1/4-RUPP autism network: Guanfacine for the treatment of hyperactivity in PDD McDougle, Christopher Q4.L.C Indiana University-Purdue University Indianapolis
Mirtazapine treatment of anxiety in children and adolescents with pervasive developmental disorders McDougle, Christopher Q4.L.C Indiana University
3/4-RUPP autism network: Guanfacine for the treatment of hyperactivity in PDD McCracken, James Q4.L.C University of California, Los Angeles
2/4-RUPP autism network: Guanfacine for the treatment of hyperactivity in PDD King, Bryan Q4.L.C Seattle Children's Hospital